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Recent successful endovascular stroke trials have provided unequivocal support for
these therapies in selected patients with large-vessel occlusive acute ischemic stroke.
In this piece, we briefly review these trials and their utilization of advanced neuroimaging
techniques that played a pivotal role in their success through targeted patient selection.
In this context, the unique challenges and opportunity for advancement in current
stroke networks’ routine delivery of care created by these trials are discussed and
recommendations to change current national stroke system guidelines are proposed.
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Recent clinical trials have endorsed a variety of advanced neuroimaging approaches to reiterate the
now unequivocal superiority of combined thrombolytic and endovascular therapy for improving
outcomes in acute ischemic stroke (AIS) patients with large-vessel occlusion (LVO). Heralding a
new era, this momentous advance in treatment has, on the one hand, created a novel challenge to
current routine clinical practice and, on the other, a tremendous opportunity to modernize current
stroke systems of care: the necessary and inevitable incorporation of advanced imaging techniques
into acute stroke. Such integration and utilization, as these trials have demonstrated, holds the key
for stroke care providers to save more brain and more stroke patients.
Advanced imaging, specifically vascular imaging, was an essential component of the recent
landmark clinical trials and their success. Multicenter Randomized Clinical Trial of Endovascular
treatment for AIS in the Netherlands (MR CLEAN), Trial and Cost Effectiveness Evaluation of
Intra-arterial Thrombectomy in Acute Ischemic Stroke (THRACE), and Assess the Penumbra
System in the Treatment of Acute Stroke (THERAPY) all required imaging evidence of LVO
for enrollment (1–3). Even more selectively, THERAPY limited inclusion to LVOs of at least
8mm in measured length (3). Extending the Time for Thrombolysis in Emergency Neurological
Deficits-Intra-Arterial (EXTEND-IA) required not only detection of LVO but also an a priori
determined favorable perfusion/ischemicmismatch profile within the affected vascular territory (4).
Endovascular treatment for small core and proximal occlusion ischemic stroke (ESCAPE) required
presence of LVO and excluded those with poor Alberta Stroke Program Early CT Score (ASPECTS)
scores and poor collateral circulation (5, 6). Similarly, Solitaire™ FR as primary treatment for acute
ischemic stroke (SWIFT-PRIME) and endovascular revascularization with solitaire device versus
best medical therapy in anterior circulation stroke within 8 h (REVASCAT) required presence of
LVO and excluded those with unfavorable ASPECTS scores (7, 8).
As a consequence of these trials’ requisite inclusion of vascular imaging, their image profiles
reflected a more comprehensive, informative assessment of acute stroke than those obtained in
routine clinical practice: one not only of tissue status but also of vascular status. More importantly,
because these trials enrolled patients with LVO across a wide range of clinical scenarios, their results
demonstrated that acute stroke imaging profiles enhanced with vascular status invaluably expanded
eligibility for and established treatment of LVO-AIS in its diverse array of clinical impairment beyond
what routine practice has offered.
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The notion that imaging which reflects both tissue and vas-
cular status may be of great benefit is not new to the field of
stroke. An abundance of evidence has progressively mounted to
modernize acute stroke management through approaches that
provide such information. For one, ASPECTS scoring is a vali-
dated method for assessing tissue status using either CT or MR
imaging (9) and indicates the likelihood of a favorable response
to treatment (5). Vascular status, although less established, has
been shown also to play a significant role in AIS (10–12). Col-
lateral flow, in particular, appears to impact acute stroke treat-
ment response: both clinical and radiographic outcomes across
all AIS and treatments are better in those with existing collat-
eral flow than in those without (10, 13). As a consequence, the
development and utilization of ASPECTS collateral scoring in
acute stroke assessment and treatment guidance has been pro-
moted within the stroke community. Furthermore, perfusion-
based methods have garnered continued support for assessment
of tissue and vascular status in acute stroke (12, 14). Evaluat-
ing therapeutic responsiveness for hypoperfusion of an affected
territory in LVO, perfusion-based imaging trials have required
vascular imaging to determine LVO status for eligibility selection.
In fact, EXTEND-IA, where a small ischemic core (<70 cm3), a
region of hypoperfusion, and a vascular occlusion were required
for entry, demonstrated a high-revascularization rate (4) and the
lowest NNT (3) of any of the recent trials, supporting the idea
that collateral flow and tissue perfusion remain tightly linked
to the success of endovascular therapy (15, 16). Even more
importantly, ongoing trials utilizing perfusion- and vascular-
based imaging have demonstrated promising early results that
further encourage and justify continued investigation of imaging
profiles in LVO-AIS thatmay bemost responsive to recanalization
therapies (17).
In essence then, advanced stroke imaging has changed how
providers can now utilize diagnostic methods to inform treat-
ment decision-making, whereas before it allowed for exclusion
of pathology (i.e., hemorrhage) (18), it now allows for active
detection of it (i.e., LVO, ischemic changes). This revolution in
applicability affords, somewhat paradoxically, the opportunity to
deliver more and better care, but only at the expense of improved
diagnostic certainty not obtained in routine clinical practice. As
a consequence, the modernization of acute stroke through uti-
lization of advancing neuroimaging requires a re-evaluation of
acute stroke triage and available diagnostic resources within the
hub-and-spoke model.
Current stroke systems of care predominantly implement a
hub-and-spoke model that links multiple primary stroke centers
(PSCs) with a comprehensive stroke center (CSC) (19). This
model provides proven excellence in stroke care for uncom-
plicated cases at all sites through compliance with established
best-care practice, but also allows for a higher level of care for
more complicated cases at CSCs when necessary (20). Best-care
practice required for PSC designation includes immediate neu-
roimaging availability for determination of thrombolysis eligi-
bility, largely achieved with non-contrast CT. However, more
advanced neuroimaging approaches, such as multimodal CT or
MRI to ascertain vascular and perfusion status, are presently not
required.
Consequently, these requirements already provide challenge to
current consensus positions on early management of LVO-AIS.
The 2013 AHA/ASA Guidelines for the Early Management
of Patients with AIS include the following recommendations:
intracranial vascular imaging when endovascular therapy is
considered (Class I, LOE A) and perfusion-based methods for
reperfusion therapies when event duration exceeds thrombolytic
eligibility windows (Class IIb, LOE B) (19). This challenge is
only magnified by the fact that the vast majority of patients
receive their initial acute stroke evaluation at PSCs: accord-
ing to the “Get with the Guidelines” registry data from 2014,
over 70%. Furthermore, although LVO comprises only a minor-
ity of this population, it carries the highest rates of disability
making its rapid identification and treatment crucial (21). As
a consequence, efficient triage and selection of LVO-AIS for
potential combined or endovascular monotherapy cannot rely
on nor succeed with the existing imaging standards of PSCs.
Because advanced imaging has now become a key determi-
nant in stroke treatment best-practice, incorporation of such
methods, particularly vascular imaging, and their rapid expert
interpretation have become a necessity of all designated stroke
centers.
Without updating this requirement for PSC designation, the
current framework within which stroke care is delivered faces
significant challenges. For one, currently designated PSCs without
at least vascular imaging capability and vascular neurology exper-
tise available for its interpretation run the grave risk of becoming
obsolete. Although these sites can administer thrombolytic ther-
apy and clinically infer presence of LVO, without vascular imaging
and its expert evaluation, they can no longer provide a definitive,
complete assessment of acute stroke rendering them ineffective
within an acute stroke system of care. In fact, a recent analysis of
over 11,000 patients in the SITS-International Stroke Thrombol-
ysis Register demonstrated that an NIHSS of 11 was moderately
predictive of LVO, though the sensitivity of this measure was only
64.5% (22), in line with prior studies suggesting that this widely
used and PSC-certification-required initial triage assessment tool
is not adequate to identify all patients with LVO (23). Thus,
this handicap will have many downstream effects within acute
stroke networks diminishing stroke care delivery overall: a priori
bypassing of centers without access to vascular imaging and/or
additional transfer to those with it leading to the disuse of certain
centers and an overburdening on and stressing of a network’s
remaining available sites, services, and resources to accommodate
this need.
With these concepts in mind, we suggest that PSC certification
(or re-certification) mandate the following new key elements: (1)
immediate availability of vascular imaging with either contrast-
enhanced CT angiography or time of flight magnetic resonance
angiography for all patients presenting with acute stroke; (2)
immediate availability of vascular neurology expertise via in-
person or telemedicine for clinical and radiologic evaluation of
acute stroke; and (3) in-place protocols within acute stroke net-
works of care for rapid identification, stabilization, and transfer of
LVO-AIS patients to CSCs or facilities of equivalence in care.
The colossal efforts to advance acute stroke care have yielded
a tremendous opportunity that should not be forsaken. More
Frontiers in Neurology | www.frontiersin.org July 2015 | Volume 6 | Article 1562
Tansy et al. Image more to save more
imaging, incorporating non-invasive angiography and multi-
modal CT or MRI, beyond the current standard of non-contrast
CT at PSCs will facilitate triage of stroke patients for current state-
of-the-art therapies to savemore brain and to extend this opportu-
nity to more patients at greatest risk of long-term disability. Such
modernization of stroke systems of care through incorporation
of advanced imaging methods and their timely interpretation in
clinical context is not just an opportunity, but an inevitable next
step that recent trial success has galvanized with a clear message:
we must image more to save more.
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